Trump preparing another exec order on drug prices

President Trump is preparing to issue an executive order that would declare a favored nations clause for drug prices, ensuring the U.S. would not pay higher prices than other countries for prescription medications, CNBC reported.

Trump spoke to reporters outside the White House last week, noting that the clause would require the U.S. to pay the same as the country with the lowest prescription drug prices. Following his statement last week, pharmaceutical stocks took a hit.

The order would mirror a proposed rule from HHS to based Medicare payments on an international pricing index, which would set payment for drugs at a target of 126% of what other countries pay.

Trump also recently issued an executive order at the end of June to enable HHS to require hospitals and insurers to disclose negotiated rates for healthcare services, as well as disclose out-of-pocket costs to patients before their procedures. Not all of Trump’s attempts to lower drug prices have been successful. A federal judge recently blocked an HHS rule that would require drugmakers to publish the list prices of drugs in TV ads.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.